



国内版 国际版

Longitudinal decrease in platelet counts as a surrogate

Sign in

ALL IMAGES VIDEOS

Add the Give with Bing extension

140,000 Results Any time

Post hoc analyses of surrogate markers of non ... - BMJ Open

<https://bmjopen.bmj.com/content/9/2/e023597>

Feb 01, 2019 · Objective One year of comprehensive continuous care intervention (CCI) through nutritional ketosis improves glycosylated haemoglobin(HbA1c), body weight and **liver** enzymes among patients with type 2 diabetes (T2D). Here, we report the effect of the CCI on **surrogate** scores of non-alcoholic fatty **liver** disease (NAFLD) and **liver fibrosis**. Methods This was a non-randomised **longitudinal** ...

Cited by: 7 Author: Eduardo Vilar-Gomez, Shaminie J Athinara...
Publish Year: 2019

Post hoc analyses of surrogate markers of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398805>

Primary outcomes: NAFLD **liver** fat and **liver fibrosis** by non-invasive **surrogate markers** . N-LFS is a **surrogate marker** of fatty **liver** that includes the presence of the metabolic syndrome, T2D, fasting serum insulin, AST and the AST/ALT ratio.

Cited by: 7 Author: Eduardo Vilar-Gomez, Shaminie J Athinara...
Publish Year: 2019

Non-invasive Markers of Liver Fibrosis: Adjuncts or ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913110>

Jun 20, 2016 · These factors, along with an acknowledgement of the need to stage disease without reliance on **liver** biopsy, have lead to an exponential interest in the identification and use of non-invasive **markers of liver fibrosis**. The performance of a non-invasive **marker of fibrosis** is measured using **liver** biopsy staging of **fibrosis** as the reference standard.

Cited by: 21 Author: Jun L. Chin, Michael Pavlides, Ahmad Mool...
Publish Year: 2016

Thrombocytopenia as a surrogate for cirrhosis and a marker ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22242>

Platelet counts reflect the severity of **liver fibrosis**, as stated above. In a hospital-based study, changes in **platelet counts** were as a **marker** for the risk of developing HCC in patients with HCV-related cirrhosis. 32 Another problem that must be addressed is the proportion of patients with HCC who exhibit thrombocytopenia.

Cited by: 182 Author: Sheng-Nan Lu, Sheng-Nan Lu, Jing-Houng ...
Publish Year: 2006

Search Tools

Turn on Hover Translation (开启取词)

Match Overview

1	Crossref 103 words "Posters (Abstracts 301-2389)", Hepatology, 2018	2%
2	Crossref 67 words "NAFLD and NASH", Springer Science and Business Media LLC, 2020	1%
3	Crossref 56 words Cheli Melzer-Cohen, Gabriel Chodick, Lise Lotte N. Husemoen, Nicolai Rhee, Varda Shalev, Avraham Karasik. "A	1%
4	Crossref 48 words "Posters (Abstracts 264-2239)", Hepatology, 2017	1%
5	Internet 46 words crawled on 09-Aug-2020 worldwidescience.org	1%
6	Internet 45 words crawled on 09-Apr-2019 jamanetwork.com	1%
7	Crossref 33 words Abhishek Chauhan, David H. Adams, Steve P. Watson, ... atricia F. Lalor. "Platelets: No longer bystanders in liver di	1%
8	Internet 31 words crawled on 17-May-2020 www.wjgnet.com	1%

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 56897

Manuscript Type: ORIGINAL ARTICLE

Case Control Study

Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis

Gotlieb N *et al.* Platelets decline predict cirrhosis

Neta Gotlieb, ¹Naama Schwartz, Shira Zelber-Sagi, Gabriel Chodick, Varda Shalev, Oren Shibolet

Abstract

BACKGROUND

Liver cirrhosis ⁵is a significant source of morbidity and mortality worldwide. The disease is usually indolent and asymptomatic early in its course while many cirrhotic patients are diagnosed late when severe complications occur. A maior challenge is to



ALL

IMAGES

VIDEOS

107,000 Results

Any time ▾

Post hoc analyses of surrogate markers of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398805>

Primary outcomes: NAFLD liver fat and liver fibrosis by non-invasive surrogate markers . N-LFS is a surrogate marker of fatty liver that includes the presence of the metabolic syndrome, T2D, fasting serum insulin, AST and the AST/ALT ratio.

Cited by: 11

Author: Eduardo Vilar-Gomez, Shaminie J Athinar...

Publish Year: 2019

[PDF] Platelet Counts and Liver Enzymes After Gastric Bypass ...

<https://link.springer.com/content/pdf/10.1007/s11695-017-3035-5.pdf>

Platelet count has been shown to be a valuable surrogate marker predicting the severity of fibrosis in NAFLD patients and could be used to predict the activity of the disease. Furthermore, high PCs are also related to cardiovascular death and all-cause mortality.

Cited by: 6

Author: Hans-Erik Johansson, Anna Wåhlén, Eric...

Publish Year: 2018

Thrombocytopenia as a surrogate for cirrhosis and a marker ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22242>

Among the individuals who were positive for anti-HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was $150 \times 10^3 / \text{mm}^3$ for a diagnosis of cirrhosis.

Cited by: 183

Author: Sheng-Nan Lu, Sheng-Nan Lu, Jing-Houn...

Publish Year: 2006

Non-invasive assessment of liver fibrosis

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959378>

Feb 27, 2011 · Individual surrogate markers of liver fibrosis. Hepatic stellate cells (HSC) represent the dominant profibrogenic hepatic cell type. Activation and subsequent transformation in fibrogenic and contractile myofibroblasts is the key event leading to extracellular matrix (ECM) deposition and increased intrahepatic resistance to blood flow (portal hypertension).

Cited by: 113

Author: Vasilios Papastergiou, Emmanuel Tsocha...

Publish Year: 2012